We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration Designed to Accelerate Development of Personalized Cancer Therapeutics

By LabMedica International staff writers
Posted on 27 Mar 2016
Two European biotechnology companies are to collaborate on the development of cell and gene based treatment strategies in order to optimize the manufacture and delivery of personalized cancer therapeutics. More...


GlaxoSmithKline (Brentford, United Kingdom) and Miltenyi Biotec (Bergisch Gladbach, Germany) recently announced an agreement to collaborate in a program to merge GlaxoSmithKline’s expertise in developing cell and gene therapy based treatments with Miltenyi Biotec’s cell processing and counting technologies.

Through the collaboration, Miltenyi Biotec will introduce greater automation and high-tech processing technology into GlaxoSmithKline’s current cell and gene therapy research and developing manufacturing capabilities. The goal is to use this increased automation to industrialize cell and gene therapies, overcoming the manufacturing constraints associated with current processes. This should reduce costs and hasten development efforts.

The collaboration will also unite the methodology and expertise of both companies to advance the discovery of new CAR (chimeric antigen-receptor) T-cell based therapeutics, in which cells are engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response.

Patrick Vallance, president of pharmaceuticals research and development at GlaxoSmithKline, said, “Cell based gene therapies are living treatments, unique to individual patients and complex to manufacture. We see tremendous potential for the cell and gene therapy platform we are building within GSK, however the complexity of current manufacturing processes limits their use to local treatment of small patient populations. Working with Miltenyi Biotec, our vision is to transform current technology so that we can expand the possibilities for cell and gene therapy treatment to wider patient populations with broader geographical reach.”

Stefan Miltenyi, CEO of Miltenyi Biotec, said, “For more than 20 years we have been developing and providing cell therapy solutions to patients worldwide. Working together with the global experts at GlaxoSmithKline, we will accelerate innovation to broaden patient access to future personalized cell and gene therapy.”

Related Links:

GlaxoSmithKline
Miltenyi Biotec



New
Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.